Gubra with improved outlook topping the charts, Danish stock to be delisted, sector continues positive trajectory

Del indlægget:
Del indlægget.

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week, Gubra increased their financial outlook for 2024, Acarix received new orders, Pila Pharma received an innovation grant, while Genmab and Gubra also had new price targets. Finally, a Danish healthcare stock announced their plans to be delisted from Nasdaq First North.

9 of the 22 Danish healthcare companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 170% return and Eurocine Vaccines was the best Nordic healthcare investment last week.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

Register for the NORDIC | IMPACT newsletter

DANISH COMPANY NEWS

Acarix

Acarix secures a multi-unit order from major cardiology practice with several offices in Florida (Link)

CADScor System is now being utilized by Leading Cardiology Practice in the New York Capital Region (Link)

Ascendis Pharma

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 (Link)

Biosergen

Biosergen publishes 2023 annual report (Link)

Cessatech

No news the past week

CS Medica

CS MEDICA Aligns Financial Priorities: Transition to Calendar Year 2024 Postponed (Link)

Curasight

No news the past week

DanCann Pharma

No news the past week

Evaxion Biotech

No news the past week

ExpreS2ion

No news the past week

Fluoguide

No news the past week

Genmab

Bernstein lowered their price target from DKK 1.662 to DKK 1.600.

Gubra

Gubra raises financial outlook for 2024 (Link)

Trading statement Q1-2024: Strong start to the year (Link)

SEB increased their price target from DKK 215 to DKK 350.

Initiator Pharma

Q1 2024 results (Link)

IO Biotech

No news the past week

Pila Pharma

PILA PHARMA RECEIVES AWARD OF INNOVATION GRANT (Link)

Saniona

Saniona reports progress on pipeline and other activities (Link)

Scandion Oncology

Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 (Link)

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments (Link)

2cureX

2CUREX AB has decided to a apply for a delisting of its shares on Nasdaq First North Growth Market in Stockholm – expected last day of trading by end of June (Link)

SELECTED CASES

Curasight

Investment Case

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance the past week of -2.1% compared to 2.6% for the KPHC index. Pila Pharma became the best-performer following recieval of an innovation grant. Acarix also did well after they got a multi-unit order from a major cardiology practice and Gubra raised their financial outlook for 2024 after a strong start of the year. Gubra now expects 15-20 organic revenue growth vs. 10-15% and an EBIT-margin of 28-31% vs. 25-28%. Finally, 2cureX announced decision to delistfrom Nasdaq First North, which the stock responded very negatively to.

The best stock year-to-date is Gubra followed by DanCann Pharma with 133-170% increases after the first 4.5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 8.3%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

The past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 2.6% to 62.49. The index has had a strong performance since end up april, and continue to recover from its all-time low in October of 57.12. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

36-98% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Eurocine Vaccines AB (98%) develops vaccine candidates from early innovation and licenses them to partners for further development and commercialization.  The activities are carried out in the bioscience cluster at Karolinska Institutet in Sweden. The stock rose following positive news in a company that Eurocine Vaccine is planning to do a reverse merger with (Link).

Hamlet BioPharma (40%) has developed a tumoricidal protein-lipid complex that mainly is used in the treatment of breast cancer, bladder cancer, as well as in cases of cancer that are hard to treat. The stock rose following positive news of IL1-RA potentially being a succssful treatment option (Link).

Redwood Pharma AB (39%) main focus is on the production of ophthalmic pharmaceuticals. The products contain active substances that are used in the treatment of dry eye disease (DED), characterised by dryness, pain, and burning. The disorder is caused by inflammation due to dysfunction of the glands as well as by the usage of contact lenses. The stock rose after two companies began due dilligence on RP501 ahead of potential commercial agreements.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites

Disclaimer 

Udvalgte investeringscases

CS Medica
Se her
Ekobot
Se her
Biosergen
Se her
Nexcom
Se her
Curasight
Se her
Mdundo
Se her
Previous slide
Next slide

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Curasight
Se her
Mdundo
Se her
Fluoguide
Se her

Mest læste indlæg

Selskabscases

Markedscases

Sectorcases

Tilbage til investeringscases

Kapital Partner A/S

Ewaldsgade 9

2200 København N
CVR: 37364843

Privatlivspolitik  –  Cookies

Skriv til os

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email